Entity
  • BioMAdvanced Diagnostics

    Created in 2021
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    909
  • Activities

  • Entity types

  • Location

    Nantes, France

    Nantes

    France

  • Employees

    Scale: 11-50

    Estimated: 12

  • SIREN

    898704457
  • Engaged corporates

    10
    6 7
  • Added in Motherbase

    1 year, 8 months ago
Description
  • Value proposition

    Disrupting the Field of Biomarkers

    BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes.

    BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers based on 20 years of translational research. Its main goal is to enable a really personalized medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians.

    More specifically, great attention is being placed towards diminishing risks for patients through minimal invasive solutions which will enable very substantial cost reductions for the Health Systems.

    The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. The identification of biomarkers to evaluate, predict and diagnose the risk of transplant rejection will provide clinicians with ways of better anticipating and adapting their patients’ treatment. The goal being to reduce as much as possible numerous secondary effects. BioMAdvanced Diagnostics Tests will provide predictive scores and will be easily integrated into diagnostic and standard treatment protocols, easy to use by medical practitioners.

    BioMAdvanced Diagnostics is incubated by Atlanpole and supported by SATT Ouest Valorisation.

    In September 2023, the company announced a 2nd round of seed investment, raising an additional 1.4 million euros.

    As of February 2024, BiomAdvanced Diagnostics is ISO 13485 certified by BSI under certificate number MD 775018.

Corporate interactions BETA
Corporate TypeTweets Articles
La French Tech Nantes
La French Tech Nantes
French Tech, IT Services and IT Consulting
La French Tech Nantes
French Tech, IT Services and IT Consulting
Other

14 Nov 2023


INRAE
INRAE
Research, Research Services
INRAE
Research, Research Services
Other

14 Jan 2024


Clermont Auvergne Innovation
Clermont Auvergne Innovation
Research, Research Services
Clermont Auvergne Innovation
Research, Research Services
Other

13 Feb 2024


CIC
CIC
Bank, Banking
CIC
Bank, Banking
Other

31 Dec 2022


Atlanpole
Atlanpole
Business Consulting and Services
Atlanpole
Business Consulting and Services
Other

22 Jan 2024


SATT Ouest Valorisation
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services
Other

9 Jan 2024


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Other

9 Jan 2024


BNP Paribas
BNP Paribas
Bank, Banking
BNP Paribas
Bank, Banking
Other

31 Dec 2022


Avolta
Avolta
Finance, Investment Banking
Avolta
Finance, Investment Banking
Other

2 Oct 2022


Atlanpole Biotherapies
Atlanpole Biotherapies
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Atlanpole Biotherapies
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Other

1 Apr 2024


Similar entities
Loading...
Loading...
Social network dynamics